Tessera Therapeutics
Tessera Therapeutics is a biotechnology firm focused on developing Gene Writing technology and non-viral delivery systems to create potentially curative therapies for major unmet medical needs.
Gene Writing Technology
Tessera Therapeutics is pioneering Gene Writing, a novel genome engineering technology aimed at embedding therapeutic messages into the genome. This approach targets the genetic source of diseases, with the potential to offer curative treatments for various conditions. The company focuses on providing accessible therapies that address significant unmet medical needs, leveraging the precision and efficacy of Gene Writing.
Tissue-Targeted Non-Viral Delivery
Tessera Therapeutics is advancing the development of tissue-targeted non-viral delivery technology. This innovative delivery method aims to facilitate precise genomic alterations directly where they are required within the body. The ultimate goal is to enhance the efficiency and effectiveness of genome engineering treatments, ensuring that therapeutic messages are optimally delivered to the targeted tissues.
Prix Galien USA 2023 Award
In 2023, Tessera Therapeutics was awarded the prestigious Prix Galien USA for Best Startup. This recognition highlights the company's pioneering contributions to the field of genome engineering and its potential to revolutionize medical treatments through its Gene Writing technology.
American Society of Gene and Cell Therapy Presentation
Tessera Therapeutics presented new data on its Gene Writing and Delivery Platforms at the American Society of Gene and Cell Therapy's 27th Annual Meeting. The presentation covered various preclinical programs, showcasing the progress and potential of their innovative technologies in advancing genome engineering solutions.